Connect Biopharma Holdings Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7578
- Today's High:
- $0.7688
- Open Price:
- $0.7688
- 52W Low:
- $0.62
- 52W High:
- $2.08
- Prev. Close:
- $0.7798
- Volume:
- 10408
Company Statistics
- Market Cap.:
- $61.10 million
- Book Value:
- 19.928
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -32%
- Return on Equity TTM:
- -56.28%
Company Profile
Connect Biopharma Holdings Ltd had its IPO on 2021-03-19 under the ticker symbol CNTB.
The company operates in the Healthcare sector and Biotechnology industry. Connect Biopharma Holdings Ltd has a staff strength of 100 employees.
Stock update
Shares of Connect Biopharma Holdings Ltd opened at $0.77 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.76 - $0.77, and closed at $0.76.
This is a -2.82% slip from the previous day's closing price.
A total volume of 10,408 shares were traded at the close of the day’s session.
In the last one week, shares of Connect Biopharma Holdings Ltd have slipped by -5.28%.
Connect Biopharma Holdings Ltd's Key Ratios
Connect Biopharma Holdings Ltd has a market cap of $61.10 million, indicating a price to book ratio of 0.1939 and a price to sales ratio of 0.
In the last 12-months Connect Biopharma Holdings Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-780296000. The EBITDA ratio measures Connect Biopharma Holdings Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Connect Biopharma Holdings Ltd’s operating margin was 0% while its return on assets stood at -32% with a return of equity of -56.28%.
In Q2, Connect Biopharma Holdings Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Connect Biopharma Holdings Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.31 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Connect Biopharma Holdings Ltd’s profitability.
Connect Biopharma Holdings Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1891. Its price to sales ratio in the trailing 12-months stood at 0.
Connect Biopharma Holdings Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.21 billion
- Total Liabilities
- $108.82 million
- Operating Cash Flow
- $-245665500.00
- Capital Expenditure
- $5.64 million
- Dividend Payout Ratio
- 0%
Connect Biopharma Holdings Ltd ended 2024 with $1.21 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.21 billion while shareholder equity stood at $1.10 billion.
Connect Biopharma Holdings Ltd ended 2024 with $0 in deferred long-term liabilities, $108.82 million in other current liabilities, in common stock, $-3175220000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $550.27 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Connect Biopharma Holdings Ltd’s total current assets stands at $1.08 billion while long-term investments were $65.74 million and short-term investments were $511.25 million. Its net receivables were $0 compared to accounts payable of $83.14 million and inventory worth $0.
In 2024, Connect Biopharma Holdings Ltd's operating cash flow was $-245665500.00 while its capital expenditure stood at $5.64 million.
Comparatively, Connect Biopharma Holdings Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.76
- 52-Week High
- $2.08
- 52-Week Low
- $0.62
- Analyst Target Price
- $6.3
Connect Biopharma Holdings Ltd stock is currently trading at $0.76 per share. It touched a 52-week high of $2.08 and a 52-week low of $2.08. Analysts tracking the stock have a 12-month average target price of $6.3.
Its 50-day moving average was $0.95 and 200-day moving average was $1.02 The short ratio stood at 2.96 indicating a short percent outstanding of 0%.
Around 3985.5% of the company’s stock are held by insiders while 4145.1% are held by institutions.
Frequently Asked Questions About Connect Biopharma Holdings Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company’s product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.